| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 28 | 2021 | 326 | 3.860 |
Why?
|
| Prostate-Specific Antigen | 7 | 2020 | 66 | 1.400 |
Why?
|
| Kidney Neoplasms | 12 | 2019 | 114 | 1.360 |
Why?
|
| Carcinoma, Renal Cell | 8 | 2019 | 75 | 0.980 |
Why?
|
| Nephrectomy | 11 | 2019 | 49 | 0.810 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 171 | 0.770 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 3 | 0.750 |
Why?
|
| Kallikreins | 1 | 2020 | 9 | 0.710 |
Why?
|
| Choice Behavior | 1 | 2021 | 76 | 0.700 |
Why?
|
| Prostatectomy | 9 | 2018 | 52 | 0.630 |
Why?
|
| Emotions | 1 | 2021 | 217 | 0.620 |
Why?
|
| Robotics | 2 | 2017 | 48 | 0.610 |
Why?
|
| Testicular Neoplasms | 3 | 2007 | 32 | 0.590 |
Why?
|
| Decision Making | 2 | 2021 | 384 | 0.580 |
Why?
|
| Watchful Waiting | 1 | 2014 | 24 | 0.470 |
Why?
|
| Urology | 1 | 2014 | 25 | 0.460 |
Why?
|
| Radiation Oncology | 1 | 2014 | 49 | 0.450 |
Why?
|
| Perception | 1 | 2014 | 178 | 0.430 |
Why?
|
| Male | 42 | 2021 | 27385 | 0.410 |
Why?
|
| Adenocarcinoma | 3 | 2008 | 321 | 0.400 |
Why?
|
| Laparoscopy | 10 | 2006 | 385 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2018 | 302 | 0.340 |
Why?
|
| Antigens, Neoplasm | 3 | 2000 | 133 | 0.330 |
Why?
|
| Humans | 50 | 2021 | 59047 | 0.320 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 349 | 0.310 |
Why?
|
| Neoplasm Metastasis | 6 | 2005 | 194 | 0.280 |
Why?
|
| Aged | 20 | 2020 | 13264 | 0.280 |
Why?
|
| Cost of Illness | 1 | 2007 | 154 | 0.260 |
Why?
|
| Health Expenditures | 1 | 2007 | 115 | 0.260 |
Why?
|
| Mesothelioma | 1 | 2006 | 26 | 0.260 |
Why?
|
| Incidental Findings | 2 | 2006 | 40 | 0.250 |
Why?
|
| Urethral Neoplasms | 1 | 2005 | 1 | 0.250 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2005 | 22 | 0.240 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2004 | 21 | 0.230 |
Why?
|
| Erythrocyte Membrane | 1 | 2004 | 24 | 0.230 |
Why?
|
| Lymphoma, B-Cell | 1 | 2004 | 59 | 0.230 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2004 | 33 | 0.230 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 98 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 41 | 0.230 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 5060 | 0.220 |
Why?
|
| Prostate | 3 | 2018 | 54 | 0.220 |
Why?
|
| Middle Aged | 18 | 2020 | 16190 | 0.220 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 2317 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2005 | 76 | 0.210 |
Why?
|
| Age Factors | 3 | 2020 | 1518 | 0.210 |
Why?
|
| Prognosis | 4 | 2021 | 1563 | 0.210 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 435 | 0.200 |
Why?
|
| Neovascularization, Pathologic | 2 | 2004 | 137 | 0.200 |
Why?
|
| Regression Analysis | 2 | 2020 | 485 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2004 | 29 | 0.190 |
Why?
|
| Adult | 15 | 2020 | 15669 | 0.190 |
Why?
|
| Kidney Transplantation | 2 | 2019 | 257 | 0.190 |
Why?
|
| Melanoma | 1 | 2005 | 335 | 0.190 |
Why?
|
| Antibodies, Neoplasm | 1 | 2000 | 27 | 0.180 |
Why?
|
| Complement C3b | 1 | 2000 | 20 | 0.180 |
Why?
|
| Michigan | 1 | 2020 | 39 | 0.180 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 452 | 0.170 |
Why?
|
| Preventive Health Services | 1 | 2020 | 72 | 0.170 |
Why?
|
| Cause of Death | 1 | 2020 | 200 | 0.170 |
Why?
|
| Advisory Committees | 1 | 2020 | 107 | 0.170 |
Why?
|
| Models, Statistical | 1 | 2020 | 307 | 0.160 |
Why?
|
| Antigens, Surface | 2 | 1996 | 190 | 0.160 |
Why?
|
| United States | 7 | 2020 | 7458 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2020 | 295 | 0.150 |
Why?
|
| Metformin | 1 | 2018 | 67 | 0.150 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2569 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 188 | 0.150 |
Why?
|
| Orchiectomy | 3 | 2007 | 28 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 260 | 0.140 |
Why?
|
| Anticarcinogenic Agents | 1 | 1998 | 76 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2020 | 346 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 419 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1205 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 865 | 0.130 |
Why?
|
| Carcinoma | 1 | 1996 | 116 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 498 | 0.120 |
Why?
|
| Androgens | 3 | 2008 | 49 | 0.120 |
Why?
|
| Risk Assessment | 5 | 2020 | 1900 | 0.120 |
Why?
|
| Neoplasm Seeding | 2 | 2005 | 3 | 0.120 |
Why?
|
| Massachusetts | 1 | 2020 | 2082 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 2 | 2005 | 240 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2004 | 73 | 0.110 |
Why?
|
| Internet | 1 | 2017 | 455 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2008 | 397 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 638 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2005 | 60 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2006 | 1453 | 0.100 |
Why?
|
| Cytokines | 1 | 1996 | 904 | 0.100 |
Why?
|
| Tea | 1 | 2011 | 26 | 0.100 |
Why?
|
| Catechin | 1 | 2011 | 31 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2017 | 1123 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 453 | 0.090 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 76 | 0.090 |
Why?
|
| Patient Preference | 1 | 2010 | 74 | 0.090 |
Why?
|
| Comprehension | 1 | 2010 | 126 | 0.080 |
Why?
|
| Retroperitoneal Space | 2 | 2006 | 20 | 0.080 |
Why?
|
| Tomography, Optical Coherence | 1 | 2011 | 199 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2006 | 10 | 0.080 |
Why?
|
| Disease Progression | 3 | 2004 | 1037 | 0.080 |
Why?
|
| Pneumoperitoneum, Artificial | 2 | 2005 | 13 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 482 | 0.070 |
Why?
|
| Female | 12 | 2019 | 30684 | 0.070 |
Why?
|
| Intraoperative Complications | 2 | 2005 | 81 | 0.070 |
Why?
|
| Suture Techniques | 2 | 2005 | 84 | 0.070 |
Why?
|
| Glutamate Carboxypeptidase II | 2 | 1996 | 7 | 0.070 |
Why?
|
| Health Resources | 1 | 2007 | 87 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2006 | 9 | 0.070 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 14 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2006 | 83 | 0.060 |
Why?
|
| Epithelium | 1 | 2006 | 95 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2006 | 91 | 0.060 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 32 | 0.060 |
Why?
|
| Congenital Abnormalities | 1 | 2005 | 22 | 0.060 |
Why?
|
| Urinary Diversion | 1 | 2005 | 5 | 0.060 |
Why?
|
| Heart Atria | 1 | 2006 | 137 | 0.060 |
Why?
|
| Vinblastine | 1 | 2005 | 18 | 0.060 |
Why?
|
| Sutures | 1 | 2005 | 33 | 0.060 |
Why?
|
| Cholestanols | 1 | 2004 | 1 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2004 | 449 | 0.060 |
Why?
|
| Warm Ischemia | 1 | 2004 | 2 | 0.060 |
Why?
|
| Cystectomy | 1 | 2005 | 15 | 0.060 |
Why?
|
| Leuprolide | 1 | 2004 | 14 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2005 | 32 | 0.060 |
Why?
|
| Penis | 1 | 2005 | 23 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 788 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2007 | 296 | 0.060 |
Why?
|
| Argon | 1 | 2004 | 3 | 0.060 |
Why?
|
| Cisplatin | 1 | 2005 | 119 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2011 | 519 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2005 | 99 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 1092 | 0.060 |
Why?
|
| Therapeutic Irrigation | 1 | 2004 | 13 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 846 | 0.060 |
Why?
|
| Methotrexate | 1 | 2005 | 76 | 0.060 |
Why?
|
| Carcinoma, Medullary | 1 | 2004 | 2 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2004 | 8 | 0.060 |
Why?
|
| Self Report | 2 | 2020 | 365 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 115 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 78 | 0.060 |
Why?
|
| Laparoscopes | 1 | 2004 | 21 | 0.060 |
Why?
|
| Demography | 2 | 2017 | 178 | 0.060 |
Why?
|
| Aorta, Abdominal | 1 | 2004 | 59 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2018 | 683 | 0.060 |
Why?
|
| Incidence | 1 | 2007 | 1232 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2004 | 102 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2006 | 204 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 894 | 0.050 |
Why?
|
| Reoperation | 1 | 2004 | 248 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2006 | 283 | 0.050 |
Why?
|
| Salvage Therapy | 2 | 2018 | 75 | 0.050 |
Why?
|
| Linear Models | 1 | 2004 | 418 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 249 | 0.050 |
Why?
|
| Orchitis | 1 | 2002 | 1 | 0.050 |
Why?
|
| Epididymitis | 1 | 2002 | 2 | 0.050 |
Why?
|
| Addison Disease | 1 | 2002 | 3 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2004 | 157 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2002 | 10 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 453 | 0.050 |
Why?
|
| Kidney | 1 | 2004 | 391 | 0.050 |
Why?
|
| Surgical Mesh | 1 | 2002 | 57 | 0.050 |
Why?
|
| Contraindications | 1 | 2001 | 45 | 0.050 |
Why?
|
| Hernia, Inguinal | 1 | 2002 | 38 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2001 | 36 | 0.050 |
Why?
|
| Biopsy | 2 | 2017 | 373 | 0.050 |
Why?
|
| Risk Factors | 2 | 2020 | 4988 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2001 | 52 | 0.050 |
Why?
|
| Bone Marrow Purging | 1 | 2000 | 1 | 0.050 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2001 | 37 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2000 | 7 | 0.050 |
Why?
|
| Rosette Formation | 1 | 2000 | 12 | 0.050 |
Why?
|
| Life Tables | 1 | 2020 | 24 | 0.050 |
Why?
|
| Immunologic Tests | 1 | 2000 | 4 | 0.050 |
Why?
|
| Immunomagnetic Separation | 1 | 2000 | 8 | 0.050 |
Why?
|
| Opsonin Proteins | 1 | 2000 | 31 | 0.050 |
Why?
|
| Marital Status | 1 | 2020 | 43 | 0.050 |
Why?
|
| SEER Program | 1 | 2020 | 65 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2000 | 112 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 1996 | 1466 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2000 | 99 | 0.050 |
Why?
|
| Liver | 1 | 2005 | 780 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 696 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 123 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2019 | 5129 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2002 | 326 | 0.040 |
Why?
|
| Hospitalization | 1 | 2007 | 1273 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 44 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 306 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2002 | 259 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 74 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 45 | 0.040 |
Why?
|
| Cyclohexanes | 1 | 1998 | 3 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2000 | 667 | 0.040 |
Why?
|
| Sesquiterpenes | 1 | 1998 | 14 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2000 | 225 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 105 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 31 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 69 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2018 | 63 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2018 | 280 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1998 | 21 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 105 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1998 | 21 | 0.040 |
Why?
|
| Lymphokines | 1 | 1998 | 66 | 0.040 |
Why?
|
| Stromal Cells | 1 | 1998 | 65 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 389 | 0.040 |
Why?
|
| Integrins | 1 | 1998 | 108 | 0.040 |
Why?
|
| Cell Communication | 1 | 1998 | 129 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 1084 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 219 | 0.030 |
Why?
|
| Length of Stay | 1 | 2000 | 761 | 0.030 |
Why?
|
| Dipeptidases | 1 | 1996 | 1 | 0.030 |
Why?
|
| Collagenases | 1 | 1996 | 14 | 0.030 |
Why?
|
| Growth Substances | 1 | 1996 | 35 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 1996 | 29 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 1998 | 201 | 0.030 |
Why?
|
| HLA Antigens | 1 | 1996 | 59 | 0.030 |
Why?
|
| Oncogenes | 1 | 1996 | 68 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1996 | 90 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1996 | 99 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1996 | 162 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1996 | 173 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 831 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 1998 | 374 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1996 | 304 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 2022 | 0.030 |
Why?
|
| Up-Regulation | 1 | 1996 | 362 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1996 | 178 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 1996 | 536 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 2004 | 126 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1996 | 580 | 0.030 |
Why?
|
| Postoperative Period | 2 | 2004 | 126 | 0.030 |
Why?
|
| Algorithms | 1 | 2017 | 984 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 104 | 0.020 |
Why?
|
| Cell Line | 1 | 1996 | 2011 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 189 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 134 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 278 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1996 | 3079 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2008 | 17 | 0.020 |
Why?
|
| Calcitriol | 1 | 2008 | 22 | 0.020 |
Why?
|
| Prednisone | 1 | 2008 | 79 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 925 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 170 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 913 | 0.020 |
Why?
|
| Signal Transduction | 1 | 1998 | 2881 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 344 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1247 | 0.020 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 2006 | 2 | 0.020 |
Why?
|
| Renal Veins | 1 | 2006 | 6 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 34 | 0.020 |
Why?
|
| Traction | 1 | 2005 | 4 | 0.020 |
Why?
|
| Polyglactin 910 | 1 | 2005 | 6 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 2004 | 6 | 0.020 |
Why?
|
| Equipment and Supplies | 1 | 2004 | 17 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 61 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2005 | 85 | 0.010 |
Why?
|
| Cryosurgery | 1 | 2004 | 23 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 2004 | 19 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2004 | 111 | 0.010 |
Why?
|
| Gene Library | 1 | 2004 | 99 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2004 | 157 | 0.010 |
Why?
|
| Egypt | 1 | 2002 | 4 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2002 | 18 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 293 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 117 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2004 | 501 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 2002 | 29 | 0.010 |
Why?
|
| Pelvis | 1 | 2002 | 57 | 0.010 |
Why?
|
| Testis | 1 | 2002 | 137 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 441 | 0.010 |
Why?
|
| Fibrosis | 1 | 2002 | 151 | 0.010 |
Why?
|
| Quality of Life | 1 | 2008 | 1103 | 0.010 |
Why?
|
| Animals | 3 | 2004 | 19549 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 24 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2005 | 5950 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2002 | 188 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 4300 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 351 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1904 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 5895 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 3552 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2001 | 201 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2002 | 381 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 546 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2000 | 709 | 0.010 |
Why?
|
| Mutation | 1 | 2001 | 2421 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 10225 | 0.010 |
Why?
|